AI assistant
Biohaven Ltd. — Director's Dealing 2026
Jan 8, 2026
31890_dirs_2026-01-07_9c8a90eb-1d22-4518-b455-65d22b1ea3ab.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Biohaven Ltd. (BHVN)
CIK: 0001935979
Period of Report: 2026-01-05
Reporting Person: Gentile Kimberly (SVP, Clinical Operations)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-05 | Common Shares | M | 3750 | — | Acquired | 101513 | Direct |
| 2026-01-05 | Common Shares | F | 1956 | $9.93 | Disposed | 99557 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | Restricted Share Unit Award | $ | M | 3750 | Disposed | Common Shares (3750) | Direct |
Footnotes
F1: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2: Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F3: The reporting person was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
F4: Not applicable.